早期姑息治疗与晚期肺癌化疗强度的全国队列关联
该回顾性队列纳入2007至2013年VA系统中23,566例IIIB或IV期肺癌患者,37%在诊断90天内接受专科早期姑息治疗(EPC)。EPC与任何化疗及高强度化疗接收减少相关,但EPC组在生命最后14天和30天内接受化疗的 odds 更高。
要点
- EPC与晚期肺癌患者任何化疗及高强度化疗的接收减少相关。
- EPC组在生命最后14天和30天内化疗 odds 反而升高。
- EPC可能通过关注生活质量优化化疗患者选择。
核心结论
- 在晚期肺癌患者中,EPC与任何化疗及高强度化疗的接收减少相关。
- 但EPC组在生命最后14天和30天内接受化疗的 odds 高于无EPC组。
研究设计与样本
- EPC定义为癌症诊断后90天内接受专科医生提供的姑息治疗。
主要发现
- 全队列中37%接受EPC,45%接受任何化疗。
- EPC组34%接受化疗,无EPC组51%接受化疗(AOR=0.55,95%CI:0.51-0.58)。
- EPC与铂类双药超过4周期(AOR=0.68,95%CI:0.60-0.77)、≥3线化疗(AOR=0.61,95%CI:0.53-0.71)、三药联合(AOR=0.68,95%CI:0.56-0.82)及2011年前厄洛替尼使用(AOR=0.66,95%CI:0.55-0.79)减少相关。
- EPC组生命最后14天(AOR=1.65,95%CI:1.44-1.87)和30天(AOR=1.67,95%CI:1.51-1.85)接受化疗的 odds 更高。
关键数值与推荐
- 高强度化疗定义包括:铂类双药超过4周期、≥3线化疗、贝伐珠单抗或西妥昔单抗三药联合、2011年前厄洛替尼使用、生命最后 days 内化疗。
- 采用逻辑回归调整患者和肿瘤特征后评估EPC与化疗接收的关联。
临床怎么用
- 对晚期肺癌患者,EPC可帮助依据体能状态、偏好和治疗目标优化化疗选择。
- 需关注EPC患者生命末期的化疗使用,避免与姑息治疗目标冲突。
局限性
- 为回顾性队列研究,可能存在残余混杂。
- 研究对象为VA系统退伍军人,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with advanced lung cancer have a poor prognosis, but both chemotherapy and early palliative care (EPC) have been shown to improve survival and quality of life (QOL). The relationship between palliative care and receipt of chemotherapy receipt is understudied. We sought to determine if EPC is associated with chemotherapy receipt and intensity among patients with advanced stage lung cancer. METHODS: Retrospective cohort study of patients in the national Veterans Health Administration (VA) with stage IIIB or IV lung cancer diagnosed between January 2007- December 2013. EPC was defined as a specialist-delivered palliative care received within 90 days of cancer diagnosis. Outcomes included any chemotherapy receipt and high-intensity chemotherapy receipt defined as: i) more than 4 cycles of a platinum-based doublet, ii) ≥3 lines of chemotherapy, iii) Bevacizumab/Cetuximab triplet therapy, iv) Erlotinib use prior to 2011, and v) chemotherapy in the last days of life. Logistic regression was used to determine the association between EPC and chemotherapy receipt after adjustment for patient and tumor characteristics. RESULTS: Among the entire cohort (N=23,566), 37% received EPC and 45% received any chemotherapy. Among those with EPC, 34% received chemotherapy compared to 51% among those without EPC (Adjusted Odds Ratio (AOR=0.55, 95% CI: 0.51-0.58). Patients who received EPC had reduced receipt of high-intensity chemotherapy including >4 cycles of platinum-based doublet (AOR=0.68, 95% CI: 0.60-0.77), ≥ 3 lines of chemotherapy (AOR=0.61, 95% CI: 0.53-0.71), triplet therapy (AOR=0.68, 95% CI: 0.56-0.82) and use of erlotinib prior to 2011 (AOR=0.66, 95% CI: 0.55-0.79). Patients with EPC were more likely to receive chemotherapy in the last 14 (AOR=1.65, 95% CI: 1.44-1.87) and 30 days (AOR=1.67, 95% CI: 1.51-1.85) of life compared to those without EPC. CONCLUSIONS: EPC was associated with reduced receipt of both any chemotherapy and high-intensity chemotherapy. However, receipt of chemotherapy at the very end-of-life was increased among patients with EPC compared to those without EPC. Among patients with advanced lung cancer, EPC may optimize patient selection for chemotherapy receipt leading to reduced use of high-intensity therapy by focusing on quality of life in accordance with patients' performance, preferences and goals of care.
引用
- Lammers A, Slatore CG, Fromme EK, et al. Association of Early Palliative Care With Chemotherapy Intensity in Patients With Advanced Stage Lung Cancer: A National Cohort Study. J Thorac Oncol. 2018. PMID: 30336324. doi:10.1016/j.jtho.2018.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。